About
Multiple Myeloma is a cancer characterized by the proliferation of a clone of plasma cells in the bone marrow and induces overproduction of immunoglobulins (antibody proteins) that crowd out the normal blood-forming cells and prevent them from functioning effectively.
The symptoms of Multiple Myeloma include bone lesions, anaemia, kidney damage and susceptibility to infections. Patients commonly experience bone pain and fractures, also experiencing weight loss, tiredness and repeated infections(2).
The tumour plasma cell clone proliferation induces high levels concentration of Monoclonal protein (also called M-Protein) which is the best tumour markers of the disease.
Multiple Myeloma Diagnosis
Serum and urine protein electrophoresis and their immunological characterisation are the gold standard for Multiple Myeloma diagnosis, for monitoring the disease and to assess the patient’s response to treatment.
Protein electrophoresis is recommended by IMWG (International Myeloma Working Group) for screening serum and urine samples for abnormalities protein detection(3).
Once the Monoclonal protein is identified (or suspected), it must be characterized by an immunofixation or immunotyping test to identify the M-Protein type (IgG, IgA, IgM, IgD, IgE) and light chain (kappa or Lambda) involved.
Sebia’s Expertise
Sebia is the world leader in diagnosis and monitoring of Multiple Myeloma patient by offering a full range of analytical solutions to enable clinicians to provide optimal medical care. Ensuring high quality results adapted to all laboratories sizes. The Sebia solution offers serum and urine protein(s) electrophoresis (SPE/UPE) for screening and identification (immunofixation/Immunotyping), measurement of FLC and follow-up monoclonal antibody therapy with HYDRASHIFT portfolio.
Featured resources on Multiple Myeloma diagnosis
See all resourcesHYDRASHIFT avoids monoclonal antibody interference on IMMUNOFIXATION
The HYDRASHIFT portfolio include IVD test to mitigate interferences seen in immunofixation result for patient treated with isatuximab or daratumumab.
Complete your Myeloma diagnostic tools with Sebia FLC Assay
The serum Free Light Chains is an important test in Prognosis and Monitoring of Multiple Myeloma patients.
Discover how the automation track integration boosted the high potential of CAPILLARYS 3
With this short video report, become aware of all the benefits of partnering with Sebia and integrate your capillary electrophoresis into the lab track automation.
Experience and recommendations of a Major Cancer Center to use HYDRASHIFT daratumumab
Immunotherapies for Multiple Myeloma, like the monoclonal antibody daratumumab, can create false positive IgG Kappa bands on Immunofixation gels. This paper describes best practice guidelines for using the Hydrashift assay to remove daratumumab interference from Immunofixation gels.
Multiple Myeloma clinical cases for diagnosis and monitoring according to latest IMWG recommendations
Educational Webinar with Prof. Alessandro Gozzetti, MD, PhD
Performance of Immunotyping vs. Immunofixation for the Detection of Monoclonal Gammopathies
Educational Webinar with Katie Thoren, PhD, Memorial Sloan Kettering Cancer Center
AL Amyloidosis: Role of clinical lab in diagnosis and management
Educational Webinar with Prof. Giovanni PALLADINI, PhD
Early detection of Multiple Myeloma: The importance of serum protein electrophoresis
Educational Webinar with Dr. Julien GUILLEMAUD
Impact of monoclonal antibody therapies on electrophoresis interpretation in myeloma patients
Educational Webinar with Dr. Rachel WHEELER
Multiple Myeloma: « 20 » and « 100 » Ratios Cut-off applicable to Sebia FLC assays
The « 20 » and « 100 » Ratios Cut-off can be used in routine with Sebia FLC assays for high-risk smoldering multiple myeloma stratification and for assessing progression to active multiple myeloma or amyloidosis.
From stand-alone to fully integrated Sebia solutions
Improve your lab performance by optimizing your Sebia solutions.
Modern Approach to Screening for Monoclonal Gammopathies Using Digital Workflows
Educational Webinar with Dr. Mark Zaydman from Washington University School of Medicine in St. Louis, MO
Challenges in Implementing Capillary Electrophoresis for Immunotyping
Educational Webinar with Dr. Jack Maggiore from Loyola University Medical Center in Chicago, IL
Clinical use of FLC testing in Multiple Myeloma and AL Amyloidosis
Educational Workshop with Pr Giovanni Palladini
Current Status of Detecting Monoclonal Antibodies and Free Light Chains in Serum
Educational Webinar with Dr. Matthias Orth from University of Heidelberg at University Hospital Mannheim.
Sebia launches M-inSight®, a test for monitoring multiple myeloma patients
Corgenix, a Sebia Group company, CAP/CLIA clinical laboratory, positions Sebia to globally commercialize M-inSight®, a novel non-invasive liquid biopsy assay for Minimal Residual Disease (MRD) monitoring in multiple myeloma
HYDRASYS 2 SCAN FOCUSING: Overview
Learn more about the HYDRASYS 2 SCAN FOCUSING for a fast and user-friendly gel electrophoresis processing.
Sebia receives U.S. FDA Clearance for the FLC Kappa & Lambda assays
Expanding offering for Multiple Myeloma and AL Amyloidosis Testing.
Sebia receives U.S. FDA Clearance for the FLC Kappa & Lambda assays
Expanding offering for Multiple Myeloma and AL Amyloidosis Testing.
Timely Diagnosis of Myeloma in Populations with Comorbidities and Health Disparities: Testing Considerations
Educational Webinar with Dr. Joseph Mikhael MD and Dr. Christopher Farnsworth, PhD
Recent Insights into Serum Free Light Chain Assays for Plasma Cell Disorders
Educational Webinar with Maria Willrich, Ph.D. and Angela Dispenzieri, M.D.
CAPILLARYS 3 TERA MC – High Capacity and Flexibility solution
Discover the new CAPILLARYS 3 TERA Features and Performance
CAPILLARYS 3 TERA MC testimonial
Watch the video to hear about the experience from one of our CAPILLARYS 3 TERA MC evolution customer.
Free Light Chains: Is the “Gold Standard” Still Really a Standard?
Educational Webinar with Pr. Oliver Frey
Upcoming events
See all eventsApr. 11, 2022 Jul. 12, 2025
IFCC Euromedlab 2021
Sebia booth: #121
Sebia Workshop: EduW22
Jun. 27, 2022 Jun. 29, 2022
IFCC Worldlab 2022
Sebia booth: #72
Sebia Workshop: EduW25
May. 22, 2023 May. 24, 2023
IFCC Euromedlab /WorldLab 2023
Sebia booth: #21
Sebia Workshop: EduW15
Apr. 10, 2025 Apr. 12, 2025
European Myeloma Network Meeting – EMN 2025
Sebia booth: #6
May. 19, 2025 May. 21, 2025
IFCC Euromedlab 2025
Sebia booth: #108
Sebia Workshop: EduW15
MINICAP FLEX-PIERCING
The compact and affordable automation of Capillary Electrophoresis.
HYDRASYS 2 SCAN FOCUSING
Large menu with high quality results on gel electrophoresis.
CAPILLARYS 3 OCTA
Evolution makes the difference.
HYDRASYS 2 SCAN FOCUSING
Large menu with high quality results on gel electrophoresis.
CAPILLARYS 3 TERA TLA
Connect our flexible electrophoresis instrument on lab automation track.
CAPILLARYS 3 TERA MC
Capillary Electrophoresis solution to meet your high capacity needs.
Serum Protein by Capillary Electrophoresis
High throughput Serum Protein Electrophoresis, with high resolution results.
Urine Protein by Capillary Electrophoresis
High throughput Urine Protein Electrophoresis, with high resolution results.
Urine Protein by Agarose Gel Electrophoresis
Proteinuria screening for renal disease.
Serum and Urine Immunotyping
Fully automated monoclonal proteins identification by Capillarys electrophoresis.
Serum and Urine Immunofixation
Identification of monoclonal proteins by agarose gel electrophoresis.
HYDRASHIFT
Avoid interferences due to therapeutic Monoclonal Antibody with HYDRASHIFT Portfolio.
Learn more about our unique technologies
(1) https://www.cancerresearchuk.org
(2) https://www.mayoclinic.org/
(3) https://www.myeloma.org/international-myeloma-working-group
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.